secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-071702
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst reports record FY2025 revenue $589M (+20% YoY); FY2026 guidance $615-645M
--------------------------------------------------------------------------------

- Full year 2025 total revenues $589.0M, up 19.8% YoY; GAAP diluted EPS $1.68 vs $1.31.
- Q4 2025 total revenues $152.6M; FIRDAPSE revenue grew 18.3% in Q4; AGAMREE grew 67.5%.
- FY2026 revenue guidance $615M-$645M; promoted product revenue expected to grow 20%+.
- Non-GAAP net income $346.2M for FY2025 vs $276.3M, up 25.3%.
- Cash and equivalents $709.2M as of Dec 31, 2025, up 37% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526071702/0001193125-26-071702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526071702/d108222d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-071702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer